⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GTBP News
GT Biopharma Inc. Common Stock
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
globenewswire.com
GTBP
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
prnewswire.com
GTBP
ADCT
STRO
CRNX
TCRX
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
globenewswire.com
ONCY
GTBP
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
prnewswire.com
GTBP
ERAS
FHTX
OABI
RXRX
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market
globenewswire.com
DGNX
GTBP
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
GTBP
GERN
KURA
SLS
TCRX
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
accessnewswire.com
GTBP
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
GTBP